BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38319805)

  • 1. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
    Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
    JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of a multigene testing for preoperative evaluation of indeterminate thyroid nodules: A prospective blinded single center study in China.
    Song Y; Xu G; Ma T; Zhu Y; Yu H; Yu W; Wei W; Wang T; Zhang B
    Cancer Med; 2020 Nov; 9(22):8397-8405. PubMed ID: 32976686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 5. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology?
    Figge JJ; Gooding WE; Steward DL; Yip L; Sippel RS; Yang SP; Scheri RP; Sipos JA; Mandel SJ; Mayson SE; Burman KD; Folek JM; Haugen BR; Sosa JA; Parameswaran R; Tan WB; Nikiforov YE; Carty SE
    Thyroid; 2021 Nov; 31(11):1673-1682. PubMed ID: 34340592
    [No Abstract]   [Full Text] [Related]  

  • 6. Performance of a Multigene Genomic Classifier in Thyroid Nodules with Suspicious for Malignancy Cytology.
    Skaugen JM; Taneja C; Liu JB; Wald AI; Nikitski AV; Chiosea SI; Seethala RR; Ohori NP; Karslioglu-French E; Carty SE; Nikiforova MN; Yip L; Nikiforov YE
    Thyroid; 2022 Dec; 32(12):1500-1508. PubMed ID: 35864811
    [No Abstract]   [Full Text] [Related]  

  • 7. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 8. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 10. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
    Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
    Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
    J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
    Witt RL
    Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 14. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
    Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
    BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
    Jug RC; Datto MB; Jiang XS
    Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplatform molecular test performance in indeterminate thyroid nodules.
    Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
    Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
    Yaprak Bayrak B; Eruyar AT
    BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
    Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
    JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
    Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
    Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management.
    Chiosea S; Hodak SP; Yip L; Abraham D; Baldwin C; Baloch Z; Gulec SA; Hannoush ZC; Haugen BR; Joseph L; Kargi AY; Khanafshar E; Livhits MJ; McIver B; Patel K; Patel SG; Randolph GW; Shaha AR; Sharma J; Stathatos N; van Zante A; Carty SE; Nikiforov YE; Nikiforova MN
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2999-3008. PubMed ID: 37071871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.